Cannabinoid-derived EHP-101 Eased Fibrosis in Systemic Sclerosis Mouse Model, Emerald Reports

Emerald Health Pharmaceuticals’ lead cannabinoid-derived treatment candidate, EHP-101, has shown potential to prevent skin and lung tissue scaring in a mouse model of systemic sclerosis, the company reports. Emerald also claims that EHP-101’s therapeutic activity is similar or superior to that seen in ajulemic acid, also known as lenabasum — a potential treatment being developed by Corbus Pharmaceuticals … Continue reading Cannabinoid-derived EHP-101 Eased Fibrosis in Systemic Sclerosis Mouse Model, Emerald Reports